Breast Imaging: Challenges and Opportunities in the Aftermath of the COVID-19 Pandemic
In a recent video interview, Amy K. Patel, MD, discussed the aftereffects of delayed breast cancer screening due to the COVID-19 pandemic, keys for improving outreach to underserved communities, legislative wins and challenges, and coalition building to educate and encourage women to resume regular breast cancer screening exams.
As we begin to emerge from the shadows of the COVID-19 pandemic, it is clear that radiologists, particularly breast radiologists, are faced with significant challenges. On top of workload issues, they may be communicating a greater number of advanced breast cancer diagnoses due to pandemic-related screening delays.
However, as Amy K. Patel, MD, points out in a recent video interview with Diagnostic Imaging, there are also emerging opportunities to save lives.
Whether it is being an advocate in legislative efforts to improve breast exam coverage, doing more outreach to underserved populations and/or building local coalitions that provide resources and support to patients, these efforts can go a long way toward emphasizing and facilitating a return to regular breast cancer screening, according to Dr. Patel, the medical director of the Breast Care Center at Liberty Hospital in Liberty, Missouri, and an assistant professor of radiology at the University of Missouri-Kansas City (UMKC) School of Medicine
For additional insights from Dr. Patel on breast imaging, watch the video below.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
